Triamterene
From Anvita Health Wiki
Contents |
Introduction
- Tradename: Dyrenium.
Indications
- management of edema & hypertension
Dosage
- Tabs: 50, 100 mg.
Pharmacokinetics
- full therapeutic effects may not be seen for several days
- absorption is variable depending upon formulation
- drug undergoes extensive 1st pass metabolism to an active metabolite
- 50-55% bound to plasma proteins
- congugate is 91% bound to plasma proteins
- both parent & conjugate are filtered & secreted renally
- elimination 1/2life is 4.1 hours & 3.1 hours for conjugate
- 1/2life is prolonged in the elderly & in patients with cirrhosis
- elimination via liver
- elimination via kidney
Adverse-effects
- hyperkalemia, especially in patients with renal failure
- nausea/vomiting
- diarrhea
- increase in blood urea nitrogen ( BUN)
- metabolic acidosis (rare)
- megaloblastic anemia (rare)
Drug-interactions
- hyperkalemia potentiated by concomitant use of ACE inhibitors, NSAIDs, diabetes
- NSAIDs can cause adverse effects of renal function & decrease diuretic effect
- drug interaction(s) of antiarrhythmic agents in combination with diuretics
- drug interaction(s) of spironolactone with potassium-sparing diuretics
- drug interaction(s) of diuretics with angiotensin II receptor antagonists
- drug interaction(s) of diuretics with ACE inhibitors
- drug interaction(s) of NSAIDs, diuretics & angiotensin II receptor antagonists
- drug interaction(s) of NSAIDs, diuretics & ACE inhibitors
Mechanism-of-action
- K+ sparing diuretic
- acts directly on distal renal tubule & collecting duct to inhibit reabsorption of Na+
- Na+, Cl-, Ca+2, & possibly HCO3- is increased
- K+ & possibly Mg+2 excretion is decreased
More General Terms
Internet Database
PubChem: 5546
References
- The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
